BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 1718686)

  • 1. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
    McTavish D; Sorkin EM
    Drugs; 1991 Jul; 42(1):65-89. PubMed ID: 1718686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.
    Haria M; McTavish D
    Drugs; 1997 Feb; 53(2):299-336. PubMed ID: 9028747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.
    Plosker GL; McTavish D
    Drugs; 1995 Aug; 50(2):334-63. PubMed ID: 8521762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
    Todd PA; Goa KL
    Drugs; 1990 Oct; 40(4):583-607. PubMed ID: 2083515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pravastatin: a review of its use in elderly patients.
    Bang LM; Goa KL
    Drugs Aging; 2003; 20(14):1061-82. PubMed ID: 14651445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
    Lea AP; McTavish D
    Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
    Ditschuneit HH; Dreyer M; Dammann HG; Ditschuneit H
    Med Klin (Munich); 1991 Mar; 86(3):142-8. PubMed ID: 1903497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pravastatin: a new drug for the treatment of hypercholesterolemia.
    Jungnickel PW; Cantral KA; Maloley PA
    Clin Pharm; 1992 Aug; 11(8):677-89. PubMed ID: 1511541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years.
    Simons LA; Nestel PJ; Clifton P; Janus ED; Simons J; Parfitt A
    Med J Aust; 1992 Nov; 157(9):584-9. PubMed ID: 1406416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.
    Eriksson M; Hådell K; Holme I; Walldius G; Kjellström T
    J Intern Med; 1998 May; 243(5):373-80. PubMed ID: 9651560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia.
    Malini PL; Ambrosioni E; De Divitiis O; Di Somma S; Rosiello G; Trimarco B
    Clin Ther; 1991; 13(4):500-10. PubMed ID: 1934003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.
    Raskin P; Ganda OP; Schwartz S; Willard D; Rosenstock J; Lodewick PA; Cressman MD; Phillipson B; Weiner B; McGovern ME
    Am J Med; 1995 Oct; 99(4):362-9. PubMed ID: 7573090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A; Rovellini A; Fiorenza AM; Sommariva D
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
    Sebestjen M; Boh M; Keber I
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR; Bacon S
    Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.